ArticleBMC pregnancy and childbirth2026
Bridging exposure and disease: serum hormones as potential mediators between PBDEs and preeclampsia.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPolybrominated diphenyl ethers (PBDEs) are associated with the development and function of the placenta, oxidative stress, and hormones vital for the pathogenesis of preeclampsia (PE). However, studies on the effects of PBDEs exposure on PE or the mediating effects of hormones are limited.
methodsThis study involved 376 pregnant women from Dongguan, China. Maternal serum was analyzed for four PBDE congeners using liquid chromatography–mass spectrometry. Notably, 19 hormones were detected using an electrochemiluminescence immunoassay.
resultsBDE-138 exhibited the highest serum level (245.50 ng/g lipid). High levels of BDE-138 exposure may increase risk of PE (odds ratio [OR] = 2.74, 95% confidence interval [CI]: 1.22, 6.18), whereas BDE-47 in a certain concentration range may reduce risk of PE (OR = 0.35, 95% CI: 0.15, 0.83). Bayesian kernel machine regression showed that an elevated mixture exposure of PBDEs within a specific range was a risk factor for PE, and BDE-209 was positively associated with risk of PE. Further, 17 α-hydroxypregnenolone and human chorionic gonadotropin were associated with an increased risk of PE (OR = 10.50, 95% CI: 2.80, 39.32 and OR = 4.22, 95% CI: 1.26, 14.12, respectively), whereas corticosterone (CORT) and aldosterone (ADS) were associated with a decreased risk of PE (OR = 0.09, 95% CI: 0.02, 0.43 and OR = 0.41, 95% CI: 0.18, 0.96, respectively). CORT levels were negatively associated with BDE-85 and BDE-138, whereas ADS levels were positively associated with them. Bayesian mediation analysis showed a potential indirect effect of BDE-85 and BDE-138 on PE mediated through CORT and ADS.
conclusionsMaternal PBDEs exposure may be associated with risk of PE, and the development of PE may be linked to a variety of hormones. Hormones may also mediate the relationship between PBDEs and PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.